- Home
- RGF vs NLSP Comparison
RGF vs NLSP Comparison
Compare RGF & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGF
- NLSP
- Stock Information
- Founded
- RGF 2016
- NLSP 2015
- Country
- RGF United States
- NLSP Switzerland
- Employees
- RGF N/A
- NLSP N/A
- Industry
- RGF Packaged Foods
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- RGF Consumer Staples
- NLSP Health Care
- Exchange
- RGF Nasdaq
- NLSP Nasdaq
- Market Cap
- RGF 8.3M
- NLSP 243.8M
- IPO Year
- RGF 2021
- NLSP 2021
- Fundamental
- Price
- RGF $0.36
- NLSP $4.96
- Analyst Decision
- RGF Hold
- NLSP
- Analyst Count
- RGF 1
- NLSP 0
- Target Price
- RGF $0.50
- NLSP N/A
- AVG Volume (30 Days)
- RGF 1.2M
- NLSP 34.6K
- Earning Date
- RGF 11-08-2024
- NLSP 11-01-2024
- Dividend Yield
- RGF N/A
- NLSP N/A
- EPS Growth
- RGF N/A
- NLSP N/A
- EPS
- RGF N/A
- NLSP N/A
- Revenue
- RGF $156,379,000.00
- NLSP N/A
- Revenue This Year
- RGF $23.67
- NLSP N/A
- Revenue Next Year
- RGF N/A
- NLSP N/A
- P/E Ratio
- RGF N/A
- NLSP N/A
- Revenue Growth
- RGF 18.88
- NLSP N/A
- 52 Week Low
- RGF $0.21
- NLSP $4.08
- 52 Week High
- RGF $2.75
- NLSP $29.68
- Technical
- Relative Strength Index (RSI)
- RGF 45.74
- NLSP 46.37
- Support Level
- RGF $0.33
- NLSP $4.52
- Resistance Level
- RGF $0.40
- NLSP $5.64
- Average True Range (ATR)
- RGF 0.04
- NLSP 0.48
- MACD
- RGF 0.00
- NLSP 0.07
- Stochastic Oscillator
- RGF 56.82
- NLSP 55.44
About RGF The Real Good Food Company Inc.
The Real Good Food Company Inc is an high-growth, branded, health- and wellness-focused frozen food company. It develops, markets, and manufactures delicious and convenient comfort foods designed to be high in protein, low in sugar, and made from gluten- and grain-free ingredients that are intended to be sold in the health and wellness segment of the frozen food category. All of its revenue is derived from the United States.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.